Company: NCNA
Filing Date: 2025-04-04
Form Type: DRS
Source: 0000950123-25-003335
Chunk: 11

Company: NuCana plc
Filing Date: 2025-04-04
Form: DRS
Chunk 11
---
 should carefully read the “Description of Securities We Are Offering” section of this prospectus. |

| ADSs outstanding prior to this offering | ADSs, each representing twenty-five ordinary shares. |

| ADSs outstanding after this offering | ADSs, each representing twenty-five ordinary shares. |

| Ordinary shares to be outstanding immediately after this offering | ordinary shares. |

| ADSs | Each ADS represents twenty-five ordinary shares, nominal value £0.0004 per ordinary share. |

| The depositary or its custodian, or a nominee of either, will hold the ordinary shares underlying your ADSs. As an ADS holder you will not be treated as one of our shareholders and you will not have shareholder rights.                        
 You will have rights as provided in the deposit agreement, as amended, or the deposit agreement. You may cancel your ADSs and withdraw the underlying ordinary shares as provided in the deposit agreement. We may amend or terminate the deposit 
 agreement without your consent. If you continue to hold your ADSs following an amendment, you agree to be bound by the terms of the deposit agreement then in effect.                                                                             |

| Depositary | Citibank, N.A., or Citibank. |

| Shareholder approvals required for offering | Under English law, certain steps necessary for the completion of this offering require the approval of our shareholders by way of an ordinary resolution 
 and a special resolution. We will receive all such                                                                                                       |

5

Confidential Treatment Requested by Nucana plc Pursuant to 17 C.F.R. Section 200.83

| required approvals prior to the completion of this offering. See “Description of Share Capital” in this prospectus. |

| Use of proceeds | We estimate that the net proceeds from this offering will be approximately $     million, at an assumed public offering price of $     per ADS or $    per Pre-Funded Warrant, and accompanying Series A Warrant and Series B Warrant, which was the closing price of our ADSs on The Nasdaq Capital Market on     , 2025, after deducting 
 the Placement Agent fees and estimated offering expenses payable by us.                                                                                                                                                                                                                                                                    |

| We intend to use the net proceeds of this offering, together with our existing cash and cash equivalents, to fund activities relating to the advancement of our drug discovery and development programs, and for other    
 general corporate purposes, including, but